| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Christopher Melton is Director at RENX and has filed Form 4s across 5 companies. Christopher Melton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $554K at current prices.
The biggest single holding is JFB (~$272K) as Director.
Christopher Melton has 28 Form 4 filings on record from June 2016 to October 2026, across 6 companies: Director at RenX Enterprises (RENX), 2024–2026; Director at Caring Brands (CABR), 2025–2026; Director at Tron (TRON), 2023–2026, and 3 more.
The 30 reported transactions were 12 stock awards, 11 option or other derivative awards, 3 option exercises and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $22K and 2 sales worth about $79K.
The only open-market purchase was 4,000 shares of SGBX at an average $5.45 on November 13, 2017, about $22K.
The largest open-market sale was 15,000 shares of TRON at an average $5.06 on August 22, 2025, about $76K. Twelve months later TRON was down 61%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.